Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers
Metrics: PDF 1048 views | HTML 1512 views | ?
Ilaria Bononi1,*, Manola Comar2,*, Andrea Puozzo1,*, Mariarita Stendardo3, Piera Boschetto3, Sara Orecchia4, Roberta Libener4, Roberto Guaschino5, Silvia Pietrobon1, Manuela Ferracin6, Massimo Negrini1,7, Fernanda Martini1, Massimo Bovenzi8, Mauro Tognon1
1Department of Morphology, Surgery and Experimental Medicine, Section of Pathology, Oncology and Experimental Biology, School of Medicine, University of Ferrara, Ferrara, Italy
2Institute for Maternal and Child Health - IRCCS “Burlo-Garofolo”– Trieste, University of Trieste, Trieste, Italy
3Department of Medical Sciences, School of Medicine, University of Ferrara, Ferrara, Italy
4Mesothelioma BioBank, Pathology Unit and City Hospital, Alessandria, Italy
5Transfusion Medicine, City Hospital, Alessandria, Italy
6Department of Experimental, Diagnostic and Specialty Medicine – DIMES, University of Bologna, Bologna, Italy
7Laboratory for Technologies of Advances Therapies (LTTA), University of Ferrara, Ferrara, Italy
8Clinical Unit of Occupational Medicine, Department of Medical Sciences, School of Medicine, University of Trieste, Trieste, Italy
*These authors have contributed equally to this work
Mauro Tognon, email: firstname.lastname@example.org
Fernanda Martini, email: email@example.com
Keywords: microRNA, mesothelioma, biomarker, asbestos, worker
Received: June 07, 2016 Accepted: September 16, 2016 Published: October 03, 2016
Malignant pleural mesothelioma (MPM), a fatal cancer, is an occupational disease mostly affecting workers ex-exposed to asbestos fibers. The asbestos, a cancerogenic mineral of different chemical composition, was widely employed in western Countries in industrial manufactures of different types. MPM may arise after a long latency period, up to five decades. MPM is resistant to conventional chemo- and radio-therapies. Altogether, these data indicate that the identification of new and specific markers are of a paramount importance for an early diagnosis and treatment of MPM. In recent years, microRNAs expression was found dysregulated in patients, both in cancer cells and sera, affected by tumors of different histotypes, including MPM. Cell and circulanting microRNAs, found to be dysregulated in this neoplasia, were proposed as new biomarkers. It has been reported that circulating microRNAs are stable in biological fluids and could be employed as potential MPM biomarkers. In this investigation, circulating microRNAs (miR) from serum samples of MPM patients and workers ex-exposed to asbestos fibers (WEA) and healthy subjects (HS) were comparatively analyzed by microarray and RT-qPCR technologies. Our results allowed (i) to select MiR-3665, an endogenous stable microRNA, as the internal control to quantify in our analyses circulating miRNAs; to detect (ii) miR-197-3p, miR-1281 and miR 32-3p up-regulated in MPM compared to HS; (iii) miR-197-3p and miR-32-3p up-regulated in MPM compared to WEA; (iv) miR-1281 up-regulated in both MPM and WEA compared to HS. In conclusion, three circulating up-regulated microRNAs, i.e. miR-197-3p, miR-1281 and miR-32-3p are proposed as potential new MPM biomarkers.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.